The comparative efficacy of various anticoagulation strategies has not been clearly established in patients with acute myocardial infarction who are undergoing percutaneous coronary intervention (PCI) according to current practice, which includes the use of radial-artery access for PCI and administration of potent P2Y 12 inhibitors without the planned use of glycoprotein IIb/IIIa inhibitors.
Bivalirudin vs. Heparin in Myocardial Infarction
A nticoagulation with heparin or bivalirudin, in combination with antiplatelet agents such as aspirin, P2Y 12 inhibitors, and glycoprotein IIb/IIIa inhibitors, is routinely used to improve angiographic and clinical outcomes in patients undergoing percutaneous coronary intervention (PCI) for acute coronary syndromes. [1] [2] [3] [4] [5] [6] The use of more potent P2Y 12 inhibitors (prasugrel, ticagrelor, and cangrelor) has further improved clinical outcomes over those seen with the use of clopidogrel, which was the previous standard treatment option for such patients. 7, 8 The goal of anticoagulant management is to balance the risk of thrombotic complications, such as reinfarction and stent thrombosis, with the risk of bleeding complications. Several trials have shown that the risk of bleeding associated with bivalirudin therapy is lower than that associated with heparin therapy. 1, 6, [9] [10] [11] However, these trials were conducted before PCI was performed with the use of routine radial-artery access and before the introduction of potent P2Y 12 inhibitors, or they did not assess the use of heparin monotherapy (without glycoprotein IIb/IIIa inhibitors) as an alternative to bivalirudin during PCI in patients with acute coronary syndromes.
Three previous trials that compared bivalirudin with heparin monotherapy in patients with acute coronary syndromes yielded conflicting results. These trials had different approaches regarding the use of heparin before randomization, bivalirudin after PCI, and potent P2Y 12 inhibitors. 5, 12, 13 The aim of the current trial was to investigate whether the use of bivalirudin would result in a lower rate of the composite of death from any cause, myocardial infarction, and major bleeding events than heparin monotherapy (without planned use of glycoprotein IIb/IIIa inhibitors) among patients with either ST-segment elevation myocardial infarction (STEMI) or non-STEMI (NSTEMI) who were undergoing PCI predominantly with the use of radial-artery access and who were receiving treatment with potent P2Y 12 inhibitors.
Me thods

Trial Design
VALIDATE-SWEDEHEART (Bivalirudin versus Heparin in ST-Segment and Non-ST-Segment Elevation Myocardial Infarction in Patients on
Modern Antiplatelet Therapy in the Swedish Web System for Enhancement and Development of Evidence-based Care in Heart Disease Evaluated according to Recommended Therapies Registry Trial) is a registry-based, multicenter, randomized, controlled, open-label clinical trial. Trial coordination, database management, and statistical analyses were performed at Uppsala Clinical Research Center. The trial was approved nationally by the ethics committee at Lund University and by the Swedish Medical Products Agency. An executive committee, with assistance from all the investigators, was responsible for the design, conduct, and reporting of the trial. The agencies that funded the trial had no access to the trial data and no role in the design, conduct, or reporting of the trial. The authors vouch for the accuracy and completeness of the data and analyses and for the fidelity of the trial to the protocol, which is available with the full text of this article at NEJM.org.
Data Sources
This trial used the platform of preexisting health care registries for enrollment, randomization, collection of data, and follow-up (for further details, see the Supplementary Appendix, available at NEJM.org). All patients at participating centers who were entered into the SWEDEHEART registry were evaluated for potential enrollment in the trial. Baseline patient demographic data were obtained from the SWEDEHEART registry, as were data on angiographic and PCI variables, in-hospital complications, and medications at baseline and at discharge, as well as International Classification of Diseases, 10th Revision hospital discharge codes. Information on death was obtained from the Swedish national population registry for all patients until the end of the trial (see the Supplementary Appendix). Answers to trial-specific questions were collected in a separate trialspecific module embedded in the SWEDEHEART online questionnaire.
Patients
Patients who were admitted to the hospital with a diagnosis of STEMI or NSTEMI and for whom urgent PCI was planned were eligible for participation in the trial if they met all other inclusion criteria and did not meet any exclusion criteria (for a complete list of inclusion and exclusion criteria, see the Supplementary Appendix).
14 Treatment with ticagrelor, prasugrel, or cangrelor before PCI was required as a condition of enroll-T h e ne w e ngl a nd jou r na l o f m e dicine ment. Patients were excluded if they had received a glycoprotein IIb/IIIa inhibitor or if use of such an agent was planned. However, emergency, unplanned use of a glycoprotein IIb/IIIa inhibitor was allowed and recorded.
In patients with STEMI, intravenous administration of up to 5000 U of unfractionated heparin was permitted before arrival at the catheterization laboratory. In all patients (i.e., those with STEMI or NSTEMI), if heparin had not been administered previously, intraarterial administration of up to 3000 U of heparin was allowed in the catheterization laboratory before angiography, in accordance with local practices. Patients who received more than 5000 U of intravenous heparin before they arrived at the catheterization laboratory or more than 3000 U of intraarterial heparin in the catheterization laboratory before they underwent angiography were excluded from the trial. All patients received pretreatment with aspirin, in accordance with local practices (usually at a dose of 300 mg orally).
Trial Procedures
In patients with STEMI, witnessed oral consent was obtained after angiography and before randomization. Within the following 24 hours, after written information about the trial had been provided, the patients confirmed further participation by providing written informed consent. In patients with NSTEMI, written consent was obtained before angiography.
After angiography but before PCI, the patients were randomly assigned, through the online Swedish Coronary Angiography and Angioplasty Registry (SCAAR; which is a component of the SWEDEHEART registry), to receive in an open-label fashion either intravenous bivalirudin (the Medicines Company) or intraarterial unfractionated heparin (LEO Pharma). Randomization was performed in a 1:1 ratio in permuted blocks, with the use of a computer-generated list, with stratification according to type of myocardial infarction (STEMI or NSTEMI) and hospital.
Bivalirudin was administered as an intravenous bolus of 0.75 mg per kilogram of body weight followed by an infusion of 1.75 mg per kilogram per hour. Treatment was started as soon as PCI of the culprit lesion was planned. Continuation of the bivalirudin infusion after PCI until completion of the last vial was strongly recommended. For the patients assigned to receive heparin, a total dose of 70 to 100 U per kilogram was recommended.
Measurement of the activated clotting time 10 minutes after the initiation of treatment with heparin or bivalirudin was strongly recommended. Administration of an additional bolus of the assigned drug (bivalirudin at a dose of 0.3 mg per kilogram or heparin at dose determined by the physician) was recommended if the activated clotting time was shorter than 250 sec. Treatment with a P2Y 12 inhibitor and aspirin (75 to 160 mg daily) was recommended for 1 year after PCI. 15 
End Points
The primary end point was the composite of death from any cause, myocardial infarction, or major bleeding events at 180 days. Secondary end points included separate analyses of the primary end point in the STEMI and NSTEMI strata, the individual components of the primary end point, stroke, and stent thrombosis. A complete list of trial end points and prespecified definitions are provided in the Supplementary Appendix. Deaths were classified as cardiovascular or noncardiovascular, and myocardial infarction was defined according to the third universal definition. We categorized major bleeding as type 2, 3, or 5 according to the Bleeding Academic Research Consortium (BARC) scale (with type 2 indicating any overt, actionable sign of bleeding; type 3 bleeding with a decrease in the hemoglobin of >3 g per deciliter, any transfusion, cardiac tamponade, or intracranial or ocular involvement; and type 5 fatal bleeding).
Research nurses screened for clinical end-point events by contacting the patients or first-degree relatives by telephone 7 days and 180 days after PCI. If a patient was suspected to have had a clinical end-point event (i.e., death, myocardial infarction, bleeding, or stroke), the patient's health care records were subjected to central blinded adjudication to determine the cause of the event according to prespecified criteria. If the patient or relatives could not be contacted after the nurses had placed repeated telephone calls and mailed a letter, information was collected through review of hospital records.
Statistical Analysis
We hypothesized that at 180 days, the rate of the composite of death from any cause, myocardial infarction, or major bleeding events would be lower among patients who had received bivalirudin than among those who had received heparin. We anticipated a rate of primary end-point events of 15.8% at 180 days in the heparin group among patients with either STEMI or NSTEMI. We estimated that a sample size of 3000 patients each in the STEMI and NSTEMI strata (a number that accounts for deviations from treatment and attrition) would provide 80% power to detect a hazard ratio for an event with bivalirudin versus heparin of 0.75 in each stratum. We estimated that a sample size of 6000 for the entire trial would provide 97.5% power to detect a hazard ratio of 0.75.
All analyses were performed on an intentionto-treat basis. Time-to-event end points are presented with the use of Kaplan-Meier plots, and treatment differences were assessed with the use of the log-rank test and Cox regression. Data on patients who were lost to follow-up were censored at the date of the last contact with the patient. The main subgroup analysis examined the primary end point and its components in the STEMI and NSTEMI strata. Additional subgroup analyses for the primary end point, which were prespecified in the statistical analysis plan, were performed with the use of a proportional-hazards model, with factors including treatment, subgroup, and interaction between treatment and subgroup. Medications at discharge were compared with the use of the chi-square test, without imputation of missing data. Two-tailed P values of less than 0.05 were considered to indicate statistical significance. All results are reported without adjustment for multiplicity.
R esult s
Trial Population
The trial was conducted at 25 of the 29 PCI centers in Sweden. Between June 2014 and September 2016, a total of 6006 patients (3005 with STEMI and 3001 with NSTEMI) underwent randomization; these patients represent 47.8% of the 12,561 patients in Sweden who presented to one of the participating centers during the enrollment period with an initial diagnosis of STEMI or NSTEMI and for whom PCI was planned (i.e., screened patients) and 70.0% of the 8585 patients who were potentially eligible for enrollment in the trial (Fig. S1 in the Supplementary Appendix). A total of 3004 patients were assigned to the bivalirudin group, and 3002 to the heparin group.
Baseline demographic and clinical characteristics for all patients enrolled in the trial and for the patients who were screened but not enrolled in the trial are shown in Table 1 . The baseline characteristics were well balanced between treatment groups. Follow-up data for the primary end point were obtained for 98.9% of the patients by means of a telephone call, review of hospital records, or both. Follow-up data on deaths were obtained for all patients from the records of the Swedish National Population Registry. Additional data on patient characteristics and medications at baseline, as well as data on completeness of follow-up, are available in Tables S1 and S2 and Figure S1 and on page 12 in the Supplementary Appendix.
PCI was performed with the use of radialartery access in 5424 patients (90.3%), with this approach used in a similar proportion of patients in the two treatment groups. The P2Y 12 inhibitor used during the procedure was ticagrelor in 5697 patients (94.9%), prasugrel in 125 (2.1%), and cangrelor in 21 (0.3%). The P2Y 12 inhibitor was administered at least 1 hour before PCI in 61.6% of the patients, and heparin (≤5000 U) was administered before arrival at the catheterization laboratory in 36.6%. Additional information on periprocedural characteristics of the patients is available in Tables S3 and S4 in the Supplementary Appendix. Crossover between the two treatment groups occurred in 0.5% of the patients. The mean maximum activated clotting time during PCI was 386 sec in the bivalirudin group and 305 sec in the heparin group. A total of 65.3% of the patients treated with bivalirudin received a prolonged infusion (mean duration, 57 min). Rescue glycoprotein IIb/IIIa inhibitor therapy was administered in 71 patients (2.4%) in the bivalirudin group and in 85 (2.8%) in the heparin group. At discharge, ticagrelor was prescribed for 5149 patients (85.7%), prasugrel for 57 (0.9%), and clopidogrel for 473 (7.9%); each P2Y 12 inhibitor was prescribed for a similar proportion of patients in the two treatment groups (Table S5 in the Supplementary Appendix).
Clinical Outcomes
The rate of the primary end point did not differ significantly between the treatment groups at 30 (Table 2) . At 180 days, a primary end-point event of death from any cause, myocardial infarction, or major bleeding had occurred in 12.3% of the patients (369 of 3004) in the bivalirudin group and in 12.8% (383 of 3002) in the heparin group (hazard ratio, 0.96; 95% confidence interval [CI], 0.83 to 1.10; P = 0.54) ( Fig. 1 and Table 3 ). Myocardial infarction had occurred in 2.0% of the patients in the bivalirudin group and in 2.4% in the heparin group (hazard ratio, 0.84; 95% CI, 0.60 to 1.19; P = 0.33), major bleeding in 8.6% and 8.6%, respectively (hazard ratio, 1.00; 95% CI, 0.84 to 1.19; P = 0.98), and definite stent thrombosis in 0.4% and 0.7%, respectively (hazard ratio, 0.54; 95% CI, 0.27 to 1.10; P = 0.09). Death had occurred in 2.9% of the patients in the bivalirudin group and in 2.8% in the heparin group (hazard ratio, 1.05; 95% CI, 0.78 to 1.41; P = 0.76). The rates of stroke and intraprocedural stent thrombosis (reported by the physician) did not differ significantly between the groups (Table 3) .
Results were consistent between patients with STEMI and those with NSTEMI and across all other prespecified subgroups, including risk groups defined according to age (>65 years vs. ≤65 years) and according to the presence or absence of chronic renal failure, diabetes mellitus, * No comparisons between treatment groups were significant. All comparisons between patients who were enrolled in the trial and screened patients who were not enrolled in the trial were significant (P<0.005), except for body-mass index (P = 0.74). Additional data are provided in Table S1 in the Supplementary Appendix. STEMI denotes ST-segment elevation myocardial infarction. † The body-mass index is the weight in kilograms divided by the square of the height in meters. ‡ Killip class II indicates the presence of rales in the lung, class III the presence of acute pulmonary edema, and class IV the presence of cardiogenic shock. (Fig. 2) . The rate of the primary end point was lower among women in the bivalirudin group than among women in the heparin group, although the interaction between sex and treatment group did not reach statistical significance (P = 0.05 for interaction) (Fig. 2) . Mortality at 180 days was lower among patients who were enrolled in the trial and underwent randomization (2.9% [172 of 6006 patients]) than among those who were screened but not enrolled in the trial (8.1% [528 of 6555]).
Discussion
In this investigator-initiated, registry-based, randomized clinical trial, we enrolled patients with acute coronary syndromes who were undergoing PCI and receiving treatment with aspirin and potent P2Y 12 inhibitors, without the planned use of glycoprotein IIb/IIIa inhibitors. In these patients, anticoagulation with bivalirudin was not superior to anticoagulation with heparin with respect to the composite end point of death from any cause, myocardial infarction, or major bleeding at 180 days. The rates of the prespecified secondary end points, including the individual components of the primary end point and stent thrombosis, did not differ significantly between the treatment groups. The results were consistent between patients with STEMI and those with NSTEMI and across major patient subgroups, regardless of baseline clinical and angiographic characteristics. The low rates of ischemic events overall and the absence of a significant between-group difference in event rates may have been influenced by the robust antithrombotic regimen used in the trial. A total of 62% of the patients received potent P2Y 12 T h e ne w e ngl a nd jou r na l o f m e dicine lower the risk of stent thrombosis and death among patients with STEMI who are undergoing primary PCI. 16, 17 A total of 65% of the patients received a prolonged infusion of high-dose bivalirudin, because previous post hoc analyses have indicated that such a regimen may prevent early stent thrombosis. 10, 18 The low rates of intraprocedural thrombotic events in the trial (1.0% in the bivalirudin group and 0.8% in the heparin group) were consistent with recently reported rates. 19 The rates of definite stent thrombosis were low at 30 days (0.3% in the bivalirudin group and 0.7% in the heparin group) and at 180 days (0.4% and 0.7%, respectively), whereas in the HEAT-PPCI (How Effective are Antithrombotic Therapies in Primary Percutaneous Coronary Intervention) trial, 5 a trial in which a prolonged infusion of bivalirudin was not used, the rate of stent thrombosis among patients with STEMI who received bivalirudin was higher (3.3% at 28 days).
As expected, the component of the primary composite end point in this trial that occurred most frequently was major bleeding, which ac- The Kaplan-Meier curves show the cumulative probability of the primary end point, which was a composite of death, myocardial infarction, or major bleeding (Panel A), as well as the cumulative probability of each component of the primary end point (Panels B, C, and D), during 180 days of follow-up. The insets show the same data on an enlarged y axis. Heparin counted for two thirds of the primary end-point events. Two thirds of all major bleeding events were moderate (BARC type 2) and one third were severe (BARC type 3 or 5). Only severe bleeding events are associated with a mortality similar to that of myocardial infarction. 20 The low and similar mortality in the two treatment groups was therefore probably due to the low rates of both myocardial infarction and severe bleeding. These findings contrast with findings from the BRIGHT (Bivalirudin in Acute Myocardial Infarction vs. Heparin and GPI Plus Heparin Trial) study, 12 which showed a lower rate of adverse clinical events (the composite of ischemic events or bleeding) with bivalirudin than with heparin; the lower rate with bivalirudin was associated primarily with a lower rate of bleeding. Two large contemporary trials that compared bivalirudin with heparin and allowed the planned use of glycoprotein IIb/IIIa inhibitors in the heparin group showed lower rates of bleeding events but higher rates of stent thrombosis in the bivalirudin group than in the heparin group. 10, 11 A subgroup analysis also showed lower rates of bleeding but higher rates of stent thrombosis in the bivalirudin group among patients for whom the planned use of glycoprotein IIb/IIIa inhibitors was not allowed. 21 In our trial, the use of the recommended radialartery access for PCI in more than 90% of the patients and the low use of glycoprotein IIb/IIIa inhibitors may have contributed to the very low rate of bleeding events in both treatment groups.
Several limitations of the trial should be noted. First, patients who were not enrolled in the trial were at higher risk for a primary endpoint event than those who were enrolled, and thus the trial population may not be representative of all patients undergoing PCI for acute myocardial infarction. Second, the trial had an open-label design, which could have biased the physicians who provided care in identifying possible outcome events. Third, follow-up data were obtained by means of telephone call or review of hospital records, and office evaluations were not planned, which may have resulted in missed outcome events or biases due to patient recall. Finally, most patients were treated with a small dose of heparin before randomization, which may have limited the likelihood of detecting a difference in effect between the trial drugs.
In summary, VALIDATE-SWEDEHEART was a registry-based, randomized, controlled trial that compared bivalirudin with heparin monotherapy among patients with STEMI or NSTEMI who were undergoing PCI predominantly with the use of a radial approach and were receiving treatment with high-intensity platelet inhibitors. We found no significant difference between treatment with bivalirudin and treatment with heparin with respect to the rate of death, repeat myocardial infarction, or major bleeding events during 180 days of follow-up. Thrombus grades range from 0 to 5, with higher grades indicating a larger thrombus. ACT denotes activated clotting time, NSTEMI non-ST-segment elevation myocardial infarction, PCI percutaneous coronary intervention, STEMI ST-segment elevation myocardial infarction, and TIMI Thrombolysis in Myocardial Infarction.
